DeVries brings technology expertise to Mirada Medical
Mirada Medical has appointed Jon DeVries as ceo. DeVries is said to be a technology visionary who has advanced AI adoption in healthcare and commercialised medical imaging solutions. Previously he helped grow Merge Healthcare’s clinical trials and enterprise imaging businesses, and redesigned Qlarity Imaging’s QuantX diagnostic AI software used to analyse breast cancer in a cloud-based software as a service solution. In addition, he was involved in the creation of the first AI offering at IBM Watson Health Imaging.
DeVries is based in Chicago and will extend Mirada’s existing presence in America. He will lead the international management team to accelerate USA and international growth, achieved through the delivery of a full suite of advanced solutions in oncology treatment guidance, and by building on a partner base that includes GE Healthcare, Boston Scientific and Philips.
“Mirada is home to some of the best scientific minds and medical software products in the world,” said DeVries. “There is huge potential for us to move the dial on improving cancer care for millions.”
DeVries aims to expand the company’s leadership in oncology treatment guidance, a critical area in cancer treatment that is seeing rapid market expansion and clinical uptake. Under DeVries, Mirada expects to accelerate its capabilities in quantitative image analysis and disease characterisation.
Chair Duane Lawrence said: “Jon’s experience and personal passions align directly with our vision to bring the very best in AI capabilities to disease characterisation, and to provide data insights on the complete patient. This makes him the perfect person to lead us into the next phase of rapid growth.”
Current ceo and founder Hugh Bettesworth will remain with Mirada as founder and non-executive director. In this role he will continue to help guide the organisation and promote the adoption of Mirada solutions around the world.
Picture: Jon DeVries
Published on page 26 of the October 2021 issue of RAD Magazine.